Nintedanib Stada Nordic (Nintedanib)

Nintedanib blocks the activity of several receptor tyrosine kinases, notably VEGFR, PDGFR and FGFR. By inhibiting these signals it reduces fibroblast proliferation, extracellular matrix formation and new blood‑vessel growth, which together help limit fibrotic tissue development and tumor vascularisation.

The specific dose of Nintedanib is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and concomitant medications. Dosage instructions are provided on the prescription label and should be followed exactly as directed by the healthcare professional.

Safety data for Nintedanib in pregnancy and lactation are limited, and the product is generally not recommended for use in pregnant or breastfeeding women. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when treating women of child‑bearing potential.

To request Nintedanib Stada Nordic, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

For idiopathic pulmonary fibrosis, the primary alternative is pirfenidone, another antifibrotic agent. While both slow disease progression, Nintedanib targets multiple tyrosine kinases and may have a broader effect on angiogenesis, whereas pirfenidone’s mechanism centers on reducing fibroblast activity. Choice between them depends on patient tolerance, comorbidities and physician judgment.

Nintedanib capsules should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight and excessive heat to maintain stability throughout its shelf life.

Nintedanib is taken orally as a capsule with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing relative to meals to minimise gastrointestinal discomfort.

The most serious adverse events include liver injury (elevated transaminases or hepatitis), significant bleeding (especially when combined with anticoagulants), and cardiovascular complications such as arterial thromboembolism or myocardial infarction. Patients should be monitored regularly for these conditions and report any concerning symptoms promptly.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any excipients, in those with severe hepatic impairment, and in pregnant or breastfeeding women. Caution is also advised for individuals with active bleeding disorders, uncontrolled hypertension, or significant cardiovascular disease.